NO792321L - Fremgangsmaate ved fremstilling av n-ethyl-gamma-pyridon-3-carboxylsyrederivater - Google Patents

Fremgangsmaate ved fremstilling av n-ethyl-gamma-pyridon-3-carboxylsyrederivater

Info

Publication number: NO792321L
Authority: NO; Norway
Prior art keywords: trimethoprim; acid; urinary tract; day; patient
Prior art date: 1978-07-13

Application number

NO792321A

Other languages

English (en)

Norwegian (no)

Inventor

Alfio Bertolini

Original Assignee

Sigma Tau Ind Farmaceuti

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-07-13

Filing date

1979-07-12

Publication date

1980-01-15

1979-07-12 Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti

1980-01-15 Publication of NO792321L publication Critical patent/NO792321L/no

Links

238000000034 method Methods 0.000 title description 3
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 35
229960001082 trimethoprim Drugs 0.000 claims abstract description 35
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims description 28
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 12
229960000210 nalidixic acid Drugs 0.000 claims description 12
229960000321 oxolinic acid Drugs 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 8
RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 claims description 8
229960004444 piromidic acid Drugs 0.000 claims description 8
208000019206 urinary tract infection Diseases 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 5
210000001635 urinary tract Anatomy 0.000 claims description 5
150000001408 amides Chemical class 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims 3
238000002560 therapeutic procedure Methods 0.000 claims 3
NFTOEHBFQROATQ-UHFFFAOYSA-N 2,3-dihydrofuran-5-carboxylic acid Chemical compound OC(=O)C1=CCCO1 NFTOEHBFQROATQ-UHFFFAOYSA-N 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
229940124530 sulfonamide Drugs 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
150000007513 acids Chemical class 0.000 description 3
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
229960001225 rifampicin Drugs 0.000 description 3
150000003456 sulfonamides Chemical class 0.000 description 3
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
229940047766 co-trimoxazole Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
241000219470 Mirabilis Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
206010035717 Pneumonia klebsiella Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
208000006750 hematuria Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000003082 hepatotoxic effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
229960005404 sulfamethoxazole Drugs 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
125000001701 trimethoxybenzyl group Chemical group 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

NO792321A 1978-07-13 1979-07-12 Fremgangsmaate ved fremstilling av n-ethyl-gamma-pyridon-3-carboxylsyrederivater NO792321L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT50274/78A IT1156860B (it)	1978-07-13	1978-07-13	Applicazione terapeutica di trimethoprim e derivati dell'acido n-etil-piridone-3 carbossilico

Publications (1)

Publication Number	Publication Date
NO792321L true NO792321L (no)	1980-01-15

Family

ID=11272626

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO792321A NO792321L (no)	1978-07-13	1979-07-12	Fremgangsmaate ved fremstilling av n-ethyl-gamma-pyridon-3-carboxylsyrederivater

Country Status (16)

Country	Link
US (1)	US4291035A (da)
JP (1)	JPS5522671A (da)
BE (1)	BE877703A (da)
CA (1)	CA1136047A (da)
CH (1)	CH639848A5 (da)
DE (1)	DE2928426A1 (da)
DK (1)	DK295079A (da)
FR (1)	FR2430770A1 (da)
GB (1)	GB2025224B (da)
IE (1)	IE48376B1 (da)
IL (1)	IL57760A (da)
IT (1)	IT1156860B (da)
LU (1)	LU81501A1 (da)
NL (1)	NL7905510A (da)
NO (1)	NO792321L (da)
SE (1)	SE7906080L (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55129227A (en) *	1979-03-28	1980-10-06	Daito Koeki Kk	Antibacterial composition
JPS58118382A (ja) *	1981-12-29	1983-07-14	Yamatake Honeywell Co Ltd	ケ−ジ弁
US20070166409A1 (en) *	2006-01-17	2007-07-19	Royds Robert B	Therapeutic compositions containing trimethoprim and cranberry extract and methods for treating and preventing urinary tract infections
US20170049779A1 (en) *	2013-02-27	2017-02-23	Okinawa Institute Of Science And Technology School Corporation	Flagellar and needle complex (injectosome) loop as anti bacterial drug target

1978
- 1978-07-13 IT IT50274/78A patent/IT1156860B/it active
1979
- 1979-07-09 IL IL57760A patent/IL57760A/xx unknown
- 1979-07-11 US US06/056,657 patent/US4291035A/en not_active Expired - Lifetime
- 1979-07-12 CH CH651879A patent/CH639848A5/it not_active IP Right Cessation
- 1979-07-12 CA CA000331653A patent/CA1136047A/en not_active Expired
- 1979-07-12 DK DK295079A patent/DK295079A/da not_active Application Discontinuation
- 1979-07-12 GB GB7924414A patent/GB2025224B/en not_active Expired
- 1979-07-12 SE SE7906080A patent/SE7906080L/xx not_active Application Discontinuation
- 1979-07-12 NO NO792321A patent/NO792321L/no unknown
- 1979-07-13 JP JP8976179A patent/JPS5522671A/ja active Pending
- 1979-07-13 NL NL7905510A patent/NL7905510A/nl not_active Application Discontinuation
- 1979-07-13 DE DE19792928426 patent/DE2928426A1/de not_active Withdrawn
- 1979-07-13 FR FR7918238A patent/FR2430770A1/fr active Granted
- 1979-07-13 BE BE0/196303A patent/BE877703A/xx not_active IP Right Cessation
- 1979-07-13 LU LU81501A patent/LU81501A1/xx unknown
- 1979-08-08 IE IE1349/79A patent/IE48376B1/en unknown

Also Published As

Publication number	Publication date
SE7906080L (sv)	1980-01-14
DK295079A (da)	1980-01-14
IE791349L (en)	1980-02-13
IL57760A (en)	1983-03-31
CH639848A5 (it)	1983-12-15
NL7905510A (nl)	1980-01-15
GB2025224A (en)	1980-01-23
CA1136047A (en)	1982-11-23
IT1156860B (it)	1987-02-04
BE877703A (fr)	1979-11-05
DE2928426A1 (de)	1980-01-31
JPS5522671A (en)	1980-02-18
FR2430770B1 (da)	1982-11-19
FR2430770A1 (fr)	1980-02-08
LU81501A1 (fr)	1979-10-31
US4291035A (en)	1981-09-22
GB2025224B (en)	1983-02-09
IT7850274A0 (it)	1978-07-13
IL57760A0 (en)	1979-11-30
IE48376B1 (en)	1984-12-26

Publication	Publication Date	Title
Pines et al.	1972	Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis
EP3360547B1 (en)	2022-07-13	Bactericidal pharmaceutical composition comprising ibuprofen
US4835140A (en)	1989-05-30	Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine
CA2440744C (en)	2009-12-08	Il-12 expression controlling agent
CN110478337A (zh)	2019-11-22	和厚朴酚及厚朴酚在制备mcr-1酶抑制剂中的应用
JP2010510973A (ja)	2010-04-08	心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用
Dance et al.	1989	Interactions in vitro between agents used to treat melioidosis
CN112957354B (zh)	2023-01-31	小白菊内酯在制备mcr-1酶抑制剂中的应用
US5354771A (en)	1994-10-11	Methods for treatment of sepsis using branch chain amino acids
Figueredo et al.	1988	Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis
US20230398139A1 (en)	2023-12-14	Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections
CN107714678B (zh)	2020-06-02	紫檀芪在制备mcr-1酶抑制剂中的应用
JPH072672A (ja)	1995-01-06	抗菌性配合製剤
JP2012502983A (ja)	2012-02-02	新規単回単位カルバペネムアミノグリコシド製剤
Yoshikawa et al.	1977	Endocarditis due to Pseudomonas aeruginosa in a heroin addict: Successful treatment with trimethoprim-sulfamethoxazole mixture plus colistin
KR20210036661A (ko)	2021-04-05	Mmagnu2 화합물을 유효성분으로 함유하는 결핵균, 비결핵 항산균 또는 그람 양성균 감염 질환 예방 또는 치료용 조성물
US4291035A (en)	1981-09-22	Pharmaceutical compositions comprising trimethoprim and N-ethyl-γ-pyridone-3-carboxylic acid derivatives
EP0621783A1 (en)	1994-11-02	Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivative
JPWO2012101846A1 (ja)	2014-06-30	インフルエンザの治療剤または予防剤
EA029149B1 (ru)	2018-02-28	Фармацевтические композиции, содержащие цефтаролина фозамил, для лечения бактериальных инфекций
KR20040010666A (ko)	2004-01-31	２ 형 인슐린 내성 당뇨병 환자의 치료를 위한 비오틴과회합된 아세틸 ｌ-카르니틴의 용도
CN101351198A (zh)	2009-01-21	使甲氧西林抗性金黄色葡萄球菌对苯唑西林敏感的组合物和方法
JP4589126B2 (ja)	2010-12-01	抗感染剤の生物学的有効性に影響を及ぼすためのクミン（ｃｕｍｉｎｕｍｃｙｍｉｎｕｍ）抽出物及びピペリンの使用
RU2614730C1 (ru)	2017-03-28	Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
Shaffer et al.	1953	Evaluation of prolonged antibiotic therapy in mice with chronic brucella infection due to Brucella melitensis